These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15510603)

  • 1. PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.
    Gelibter A; Milella M; Ceribelli A; Zeuli M; Ferraresi V; Vecchione A; Cognetti F
    Anticancer Res; 2004; 24(5B):3147-51. PubMed ID: 15510603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib].
    Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla JF; Sainz-Esteban A; Barragán J; Portilla-Quattrociocchi H; Carril JM
    Rev Esp Med Nucl; 2008; 27(3):168-75. PubMed ID: 18570858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
    Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
    J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography.
    Heinicke T; Wardelmann E; Sauerbruch T; Tschampa HJ; Glasmacher A; Palmedo H
    Anticancer Res; 2005; 25(6C):4591-4. PubMed ID: 16334147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response--an AGITG study.
    Goldstein D; Tan BS; Rossleigh M; Haindl W; Walker B; Dixon J
    Oncology; 2005; 69(4):326-32. PubMed ID: 16293972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
    Desai J; Shankar S; Heinrich MC; Fletcher JA; Fletcher CD; Manola J; Morgan JA; Corless CL; George S; Tuncali K; Silverman SG; Van den Abbeele AD; van Sonnenberg E; Demetri GD
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5398-405. PubMed ID: 17875769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imatinib mesylate (glivec) as a treatment for gastrointestinal stromal tumor (GIST)--long term follow-up].
    Raccah E; Merimsky O; Kuten A; Apter S; Catane R
    Harefuah; 2007 May; 146(5):329-34, 408. PubMed ID: 17674545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New strategies for treating GIST when imatinib fails.
    Boyar MS; Taub RN
    Cancer Invest; 2007 Aug; 25(5):328-35. PubMed ID: 17661208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report.
    Hughes B; Yip D; Goldstein D; Waring P; Beshay V; Chong G
    BMC Cancer; 2004 Oct; 4():74. PubMed ID: 15473910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate.
    Abhyankar SA; Nair N
    Clin Nucl Med; 2008 Mar; 33(3):213-4. PubMed ID: 18287851
    [No Abstract]   [Full Text] [Related]  

  • 11. Response evaluation of gastrointestinal stromal tumors.
    Choi H
    Oncologist; 2008; 13 Suppl 2():4-7. PubMed ID: 18434631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.
    Shankar S; Dundamadappa SK; Karam AR; Stay RM; van Sonnenberg E
    Acta Radiol; 2009 Oct; 50(8):837-44. PubMed ID: 19735005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of extension of gastrointestinal stromal tumors (GIST) treated with imatinib (Gleevec®) by 18F-FDG PET/CT.
    Valls-Ferrusola E; García-Garzón JR; Ponce-López A; Soler-Peter M; Fuertes-Cabero S; Moragas-Solanes M; Riera-Gil E; Carrió-Gasset I; Lomeña-Caballero F
    Rev Esp Enferm Dig; 2012 Jul; 104(7):360-6. PubMed ID: 22849497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J; Connock M; Song F; Yao G; Fry-Smith A; Raftery J; Peake D
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
    AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate.
    Ryu MH; Lee JL; Chang HM; Kim TW; Kang HJ; Sohn HJ; Lee JS; Kang YK
    Jpn J Clin Oncol; 2006 Jan; 36(1):17-24. PubMed ID: 16418188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors].
    García-González J; Sánchez Salmón A; Areses Manrique C; León Mateos L; Barandela Salgado J; López López R
    Rev Esp Med Nucl; 2007; 26(2):100-2. PubMed ID: 17386236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.
    Lai IR; Hu RH; Chang KJ
    Hepatogastroenterology; 2005; 52(63):826-8. PubMed ID: 15966213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate.
    Goh BK; Chow PK; Chuah KL; Yap WM; Wong WK
    Eur J Surg Oncol; 2006 Nov; 32(9):961-3. PubMed ID: 16842963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.